# Synthesis of 3-O-sialyl and 6-O-sulfo derivatives of dimeric N-acetyl lactosamine as specific acceptors for $\alpha$ -1-fucosyltransferases

### Rakesh K. Jain,† Bao-Guo Huang, E. V. Chandrasekaran and Khushi L. Matta\*

Department of Gynecologic Oncology, Rosewell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY 14263, USA

## The stereoselective syntheses of 3-O-sialyl and 6-O-sulfo dimeric lactosamine derivatives 1-4 are accomplished through the use of key glycosyl donors 13 and 15.

In continuation of our efforts towards the synthesis of biologically important oligosaccharides, we have developed an elegant synthesis of 3-O- and 6-O-substituted dimeric lactosamine derivatives. 1-41 (Fig. 1), which were prepared from the key intermediates 5-13 (Fig. 2) by stereoselective transformation, as described in Schemes 1–3. Our approach is based upon the observation that an O-acetyl group can be selectively removed in the presence of a 6-O-pivaloyl substituent to give 6-O-pivaloyl β-d-galactopyranosyl linked compounds. Glycosylation of 5 with 9 under Mukaiyama's conditions (SnCl<sub>2</sub>-AgOTf)<sup>2</sup> followed by acetylation with pyridine-acetic anhydride afforded the  $\beta(1\rightarrow 3)$  linked disaccharide 14 in 8% yield and the  $\beta(1\rightarrow 4)$  linked disaccharide 15 in 48% yield. The <sup>1</sup>H NMR spectrum of 15 displayed characteristic signals for H-3, H-1 ( $\delta$  5.71–5.67), H-1' ( $\delta$  4.50, d, J = 8.0 Hz),  $4 \times OAc$  ( $\delta$ 2.08, 2.04, 1.93 and 0.86) and  $2 \times \text{CMe}_3$  ( $\delta$  1.25 and 1.17). Isopropylidenation of 11, using Catelani's procedure,<sup>3</sup> followed

Fig. 1 Target molecules sialyl and sulfated dimeric lactosamine 1-4

OPiv
OPiv
OBn
HO
R
NPhtth
$$\mathbf{5}$$
 R = SPh
 $\mathbf{6}$  R = OBn

AcO
OPiv
OBn
OAc
NPhtth
 $\mathbf{11}$ 
 $\mathbf{12}$  R<sup>1</sup> = OMe, R<sup>2</sup> = H
 $\mathbf{13}$  R<sup>1</sup> = SPh, R<sup>2</sup> = Ac

Fig. 2 Key intermediates 5-13 involved in the synthesis of target molecules  $\frac{1}{4}$ 

by acetylation with pyridine-acetic anhydride and deacetonation provided the acceptor 16 in 66% yield. The <sup>1</sup>H NMR spectrum gave characteristic signals at δ 5.70 (dd, H-3), 2.10 and 1.09 (2  $\times$  OAc) and 1.27 and 1.23 (2  $\times$  CMe<sub>3</sub>). Condensation of the donor 15 with 16 under NIS-triflic acid conditions at -30 °C gave 17 in 76% yield. The <sup>1</sup>H NMR spectrum of 17 displayed characteristic signals at  $\delta$  5.71–5.59 (2  $\times$  dd and d, H-3, H-3" and H-4"), 5.46 (d, J = 8.3 Hz, H-1"), 5.24 (d, J = 8.5 Hz, H-1), 5.09 (dd, H-2'''), 4.97 (dd, H-2'), 4.53(d, J = 7.9 Hz, H-1'''), 4.43 (d, J = 7.6 Hz, H-1'), 2.10-1.49(cluster of singlets,  $6 \times \text{OAc}$ ) and 1.25, 1.23 and 1.94 (4  $\times$ CMe<sub>3</sub>) which confirmed a  $\beta(1\rightarrow 3)$  conformation of the newly incorporated glycosidic linkage. De-O-acetylation of 17 in MeOH–CH<sub>2</sub>Cl<sub>2</sub> (1:1, v/v) with MeOH–MeONa (pH 10) at 0 °C provided the acceptor 18 in 95% yield. The <sup>1</sup>H NMR spectrum gave characteristic signals at  $\delta$  5.58–5.69 (2 × dd, H-3" and  $\tilde{H}$ -3), 5.34 (d, H-1", J = 8.2 Hz), 5.24 (d, H-1, J = 8.4 Hz), 4.82 (dd, H-2'), 4.73 (d, J = 7.8 Hz, H-1'''), 4.35 (d, J = 7.7 Hz,H-1'), 1.84, 1.75 and 1.49 (each s,  $3 \times OAc$ ) and 1.25, 1.23, 1.22 and 0.97 (each s, 4 × CMe<sub>3</sub>) confirming the assigned structure.

Scheme 1 Reactions and conditions: i, **5** (1.0 equiv.), **9** (1.5 equiv.), AgOTf (1.20 equiv.), 4 Å molecular sieves,  $CH_2CI_2$ -toluene (5:1, v/v), -15 °C to room temp., 5 h; ii, pyridine-Ac<sub>2</sub>O (2:1, v/v); iii, 0.15% CSA, DMP, 24 h, MeOH-H<sub>2</sub>O (10:1, v/v), 100 °C, 6 h; iv, 70% aq. AcOH, 70 °C, 2 h; v, **15** (1.05 equiv.), or **10** (3.0 equiv.), NIS (3.0 equiv.)-triflic acid, -30 °C, 2 h; vi, MeOH-CH<sub>2</sub>CI<sub>2</sub> (1:1, v/v), MeONa (pH 10), 2 h; vii, SO<sub>3</sub>-pyridine complex in pyridine (6.0 equiv.), 5 °C, 16 h; viii, MeOH-hydrazine hydrate (4:1, v/v), 100 °C, 16 h, Ac<sub>2</sub>O (excess), MeOH-CH<sub>2</sub>CI<sub>2</sub> (1:1, v/v), 0 °C, 1 h; ix, MeOH-MeONa, 24 h; x, LiI (10 equiv.), pyridine, 120 °C, 3 h

Scheme 2 Reagents and conditions: i, MeOH–CH<sub>2</sub>Cl<sub>2</sub> (1:1, v/v), MeONa, 0 °C, 2 h, 85%; ii, DMP, PTS, room temp., 1.5 h, 89%; iii, pyridine–Ac<sub>2</sub>O (2:1, v/v), room temp., 12 h, 89%; iv, 70% aq. AcOH, 65 °C, 2.5 h, 66%; v, 13 (0.95 equiv.), NIS (3.0 equiv.)—triflic acid, -20 °C, 1 h, 54%; vi, EtOH–hydrazine hydrate (4:1, v/v), 100 °C, 16 h, pyridine–Ac<sub>2</sub>O (2:1, v/v), room temp., 12 h, 84%; vii, 10% Pd–C, H<sub>2</sub>, MeOH, 16 h; 50%; viii, SO<sub>3</sub>–pyridine complex in DMF (10 equiv.), 0 °C, 16 h; ix, MeOH–MeONa, 16 h; Na<sup>+</sup> resin, 35% from 22

Removal of both the phthalimido and acetate groups from 20 was accomplished by treatment with hydrazine hydrate in ethanol (1:9, v/v) at 80 °C followed by N-acetylation to give 23 in 65% yield. Condensation of sialic acid donor 10 with 23 at -40 °C followed by *O*-acetylation gave 24 in 35% yield (based on 23 consumed). The synthesis of 4 from 24 was achieved by a sequence of reactions similar to those described for the preparation of 3 from 21. The structures of 1–4 were confirmed by <sup>1</sup>H and <sup>13</sup>C NMR spectroscopy.†

Our preliminary examination of Gal $\beta$ 1,4(6-sulfo) GlcNAc $\beta$ 1,3 Gal $\beta$ 1,4(6-sulfo) GlcNAc $\beta$ -O-Me (3) and Neu-Ac $\alpha$ 2,3Gal $\beta$ 1,4(6-sulfo)GlcNAc $\beta$ 1,3Gal $\beta$ 1,4(6-sulfo)

GlcNAc $\beta$ -O-Me (4) indicated that both of these compounds were equally active as acceptors for human colon tumour  $\alpha 1,3$ -1-fucosyltransferase.

These investigations were supported by Grant No. CA 63218 awarded by the National Cancer Institute.

### **Footnote**

† Selected data for 1:  $[\alpha]_D$  7 (c 1.5,  $H_2O$ ) [lit., $^{12}$  -12.2 (c 0.5,  $H_2O$ )];  $^{13}C$  NMR ( $D_2O$ , 100.6 MHz):  $\delta$  101.86 (C-1"), 101.72 (C-1'), 101.45 (C-1"), 98.81 (C-1), 81.04 (C-3'), 77.49 (C-3"), 73.89 (C-4"), 73.85 (C-4), 59.90 (C-6" and C-6'), 59.09 (C-6"), 58.85 (C-6), 54.19 (C-2"), 53.99 (C-2). For 2:  $[\alpha]_D$  +186 (c 0.2,  $H_2O$ );  $^{1}H$  NMR ( $D_2O$ , 400 MHz):  $\delta$  4.84 (d, J = 12 Hz,

Scheme 3 Reagents and conditions: i, EtOH–hydrazine hydrate (9:1, v/v), 80 °C, 1 h, MeOH–Et<sub>3</sub>N–Ac<sub>2</sub>O (4:2:1), room temp., 2 h, 65%; ii, **10** (2.50 equiv.), NIS (3.0 equiv.)–triflic acid, MeCN, -40 °C, 1 h; iii, pyridine–Ac<sub>2</sub>O (2:1, v/v), room temp., 12 h, 35% based on **23** consumed; iv, 10% Pd–C, H<sub>2</sub> MeOH, 24 h; v, SO<sub>3</sub>–pyridine complex in DMF (10 equiv.), room temp., 2 h; vi, MeOH–MeONa, 48 h; H<sub>2</sub>O, 4 h, Na<sup>+</sup> resin, 56% from **24** 

Selective sulfation of **18** with SO<sub>3</sub>–pyridine complex in pyridine at 5 °C provided the 3-*O*-sulfo compound which upon removal of its phthalimido group (MeOH–hydrazine hydrate, 100 °C) and *N*-acetylation followed by de-*O*-acetylation (MeOH–MeONa) gave the known compound **1** (55% from **18**).<sup>4</sup>

A similar NIS-triflic acid reaction of **18** with sialic acid donor **10** provided the crude pentasaccharide. The conversion of this intermediate into target compound **2** (23% from **18**) was then carried out in 4 steps: (i) LiI-pyridine (methyl ester to acid), (ii) MeOH-hydrazine hydrate (phthalimido group removal), (iii) Ac<sub>2</sub>O-MeOH-CH<sub>2</sub>Cl<sub>2</sub> (*N*-acetylation) and (iv) MeOH-MeONa (de-*O*-acetylation).

The synthesis of 3 and 4 (Schemes 2 and 3) involved the glycosylation of 8 with fluoride 9 under conditions similar to those described for the preparation of 15 (from 5), followed by acetylation to give donor 13 along with some 1→3 linked disaccharide. Condensation of 13 with 19 under NIS−triflic acid conditions at −20 °C provided 20 in 54% yield. The formation of 21 from 20 was achieved by the treatment with hydrazine hydrate in ethanol (1:4, v/v) at 100 °C followed by acetylation with pyridine–acetic anhydride in 84% yield. The removal of *O*-benzyl (10% Pd–C) gave diol 22 which on sulfation with SO<sub>3</sub>−pyridine complex in DMF and followed by de-*O*-acetylation gave compound 3 in 35% yield (from 22).

H-1"), 4.69 (d, J=11.0 Hz, H-1), 4.50 (d, J=8.0 Hz, H-1"), 4.41 (d, J=8.0 Hz, H-1'), 2.71 (dd, J=4.6 Hz, H-3""e), 1.99 and 1.88 (each s, 3×NAc), 1.75 (t, J=1.2 Hz, H-3""a);  $^{13}$ C NMR:  $\delta$  101.86 (C-1"), 101.73 (C-1'), 101.55 (C-1"), 98.79 (C-1), 81.04 (C-3'), 77.49 (C-3"'), 74.49 (C-4"), 74.15 (C-4), 61.58 (C-9""), 59.99 (C-6"), 59.91 (C-6'), 59.09 (C-6"), 58.86 (C-6), 54.17 (C-2"), 53.99 (C-2), 50.68 (C-5"), 38.63 (C-3""); m/z 1128.5 (M — Na) — For 3:  $[\alpha]_D$  +21 (c 0.6, H<sub>2</sub>O);  $^{13}$ C NMR:  $\delta$  101.84 (C-1""), 101.67 (C-1"), 101.56 (C-1"), 100.94 (C-1), 81.46 (C-3'), 76.88 (C-3""), 74.33 (C-4"), 74.05 (C-4), 67.63 (C-6"), 67.36 (C-6), 60.11 (C-6"), 60.02 (C-6'), 56.19 (OMe), 54.15 (C-2"), 53.91 (C-2); m/z 942.9 (M — Na) — For 4:  $[\alpha]_D$  +24 (c 0.7, H<sub>2</sub>O);  $^{13}$ C NMR:  $\delta$  101.84 (C-1""), 101.60 (C-1'), 101.15 (C-1"), 100.92 (C-1), 98.73 (C-2""), 81.50 (C-3'), 76.79 (C-3""), 74.29 (C-4"), 74.02 (C-4), 67.29 (C-6"), 67.08 (C-6), 61.52 (C-9""), 60.01 (C-6' and C-6""), 56.17 (OMe), 54.09 (C-2"), 53.06 (C-2), 50.60 (C-5""), 38.57 (C-3"").

### References

- 1 R. K. Jain, R. Vig, R. D. Locke, A. Mohammad and K. L. Matta, *J. Chem. Soc., Chem. Commun.*, 1996, 65.
- 2 T. Mukaiyama, Y. Murai and S. Shoda, *Chem. Lett.*, 1981, 431; T. Mukaiyama, Y. Hashimoto and S. Shoda, *Chem. Lett.*, 1983, 935.
- 3 G. Catelani, F. Colonna and A. Marra, *Carbohydr. Res.*, 1988, **182**, 297.
- 4 G. V. Reddy, R. K. Jain, R. D. Locke and K. L. Matta, *Carbohydr. Res.*, 1996, 280, 261.

Received, 5th August 1996; Com. 6/05439K